Patients were allocated to three treatment groups – subcutaneous Cosentyx 150 mg with a loading dose taken weekly for four weeks, then a monthly maintenance dose, Cosentyx 150 mg taken monthly ...
The trial included 800 patients with active PsA who hadn’t been treated before with biologic drugs and received either Cosentyx or Humira once a month after weekly lead-in dosing over a 48-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback